Bg pattern

COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the Patient

Coagadex 250 UI Powder and Solvent for Solution for Injection

Coagadex 500 UI Powder and Solvent for Solution for Injection

Human Coagulation Factor X

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor or pharmacist.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

Contents of the Package Leaflet

  1. What is Coagadex and what is it used for
  2. What you need to know before you use Coagadex
  3. How to use Coagadex
  4. Possible side effects
  5. Storage of Coagadex
  6. Contents of the pack and other information

1. What is Coagadex and what is it used for

Coagadex is a human coagulation factor X concentrate, a protein that is necessary for blood to clot. The factor X in Coagadex is extracted from human plasma (the liquid part of the blood). It is used to treat and prevent bleeding in patients with hereditary factor X deficiency, also during surgery.

Patients with hereditary factor X deficiency do not have enough factor X in the blood for proper clotting, which leads to excessive bleeding. Coagadex replaces the missing factor X and allows the blood to clot normally.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use Coagadex

Do not use Coagadex:

  • if you are allergic to human coagulation factor X or to any of the other ingredients of this medicine (listed in section 6).

Check with your doctor if this applies to you.

Warnings and precautions

Consult your doctor, pharmacist or nurse before starting treatment with Coagadex:

  • if you have more intense or prolonged bleeding than usual and if the bleeding does not stop after injection of Coagadex;
  • if you are taking a medicine to prevent blood clots that works by blocking factor Xa. These medicines may make Coagadex not work.

Some patients with insufficient factor X may develop inhibitors (antibodies) to factor X during treatment, which could prevent the medicine from working properly. Your doctor will regularly check for the presence of these antibodies, especially before surgery. Before and after treatment with this medicine, especially during the first cycle, your doctor will likely perform tests to check your factor X level in the blood.

Viral safety

When administering medicines derived from human blood or plasma, certain measures must be taken to prevent the transmission of infections to the recipient. These measures include:

  • careful selection of blood and plasma donors to exclude those who may transmit infections,
  • analysis of donated plasma for viruses/infections,
  • inclusion of steps that inactivate or remove viruses when processing blood or plasma.

These measures are considered effective for the following viruses: human immunodeficiency virus (HIV), hepatitis B virus, hepatitis C virus, hepatitis A virus, and parvovirus B19. Despite these measures, when administering medicines derived from human blood or plasma, the possibility of transmitting infections cannot be completely excluded. This also applies to unknown or emerging viruses and other types of infections.

It is strongly recommended that each time you receive a dose of Coagadex, you note the name and batch number of the product in order to maintain a record of the batches used.

If you regularly or repeatedly receive products with factor X derived from human plasma, your doctor may recommend that you consider vaccination against hepatitis A and B.

Children and adolescents

The warnings and precautions for adults mentioned also apply to children (2 to 11 years old) and adolescents (12 to 18 years old).

Using Coagadex with other medicines

Tell your doctor if you are taking, have recently taken, or might take any other medicines.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.

Driving and using machines

No effects on the ability to drive or use machines have been observed.

Coagadex contains sodium

This medicine contains up to 9.2 mg of sodium (a major component of table/cooking salt) in each milliliter of solution. This is equivalent to 0.0046% of the maximum daily recommended sodium intake for an adult.

3. How to use Coagadex

Treatment should be initiated by a doctor experienced in the treatment of coagulation disorders.

Follow the administration instructions for this medicine exactly as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.

Coagadex must be injected directly into a vein. Before injecting this product at home, a healthcare professional must have provided training on how to do it.

Your doctor will explain how much to use, when to use it, and for how long. The dose indicated by your doctor will generally be the number of complete vials that contain the appropriate dose for you. Do not administer more than 60 UI/kg daily in any age group.

Use in adults

How much Coagadex is administered to treat a bleed or to prevent future bleeds?Your doctor will tell you how much Coagadex to administer to treat a bleed and to prevent future bleeds; the required dose will depend on your normal factor X levels in the blood.

How much is administered before, during, and after major surgery?

Before:The dose of Coagadex used should be sufficient to increase the factor X in the blood to a level between 70 and 90 units/dl. The dose you need will depend on your normal factor X levels in the blood and will be calculated by your doctor.

After:During the first days after surgery, the factor X concentration in plasma will be regularly monitored. It is recommended that your factor X level in the blood be maintained above 50 units/dl. Your doctor will calculate the dose you need.

If your blood factor X concentration is too low (your doctor will assess this), or if it decreases more rapidly than expected, it may be due to the presence of a factor X inhibitor that prevents the medicine from working properly. Your doctor will order the appropriate clinical tests to see if this is the case.

How much is administered regularly for long-term prevention of bleeds?

Your doctor will tell you if this use is suitable for your case and, if so, the corresponding dose.

Use in children and adolescents

Your doctor will recommend a suitable dose for you or your child. Doses for children under 12 years old are generally higher than doses for adolescents and adults. Doses for adolescents will be similar to those for adults.

When to inject Coagadex

  • The medicine should be injected when the first sign of bleeding appears.
  • The injection should be repeated as necessary to stop the bleeding.
  • The severity of each bleed should be judged individually.
  • The first time you use this medicine, you will be supervised by your doctor.

Dissolving the medicine before use

Your medicine must onlybe dissolved in the solvent provided with the product.

Amount of Coagadex

Volume of solvent

250 UI

2.5 ml

500 UI

5 ml

Coagadex is provided with the amount of solvent as shown in the table.

You can dissolve this medicine using the Mix2Vial needle-free transfer device included in the pack.

Place the Coagadex vials at room temperature before mixing. Constitute the medicine as follows:

Three transparent glass vials with silver caps and blue rubber rings on a reflective surface

Step 1:

  • Remove the cap from the powder vial and clean the end of the stopper with an alcohol swab.
  • Repeat this step for the solvent vial.
  • Remove the top part of the transfer device package, but do not remove the device from the package.

Transparent sterile filter with blue activated carbon inside a clear plastic container on a circular base

Step 2:

  • Place the blue end of the transfer device onto the solvent vial and press until the tip penetrates the rubber stopper and clicks into place.
  • Remove the outer plastic packaging of the transfer device and

discard it, being careful not to touch the exposed end of the device.

Two transparent medicine vials and one blue vial with superimposed rubber stoppers vertically on a light background

Step 3

  • Invert the solvent vial with the transfer device still attached.
  • Place the transparent end of the transfer device over the powder vial and

press until the tip penetrates the rubber stopper and clicks into place.

Transparent medical device with interconnected blue components for fluid administration

Step 4:

  • The solvent will pass into the powder vial by vacuum.
  • Gently turn the vial to ensure the powder is well mixed.

Do not shake the vial.

  • • A clear, transparent, or slightly opalescent solution should be obtained, usually within about 1 minute (maximum 5 minutes).

Transparent syringe with liquid and graduated scale over a medicine vial with a black cap

Step 5:

  • Separate the empty solvent vial and the blue part of the transfer device from the transparent part by unscrewing in a counterclockwise direction.
  • Take an empty syringe (not provided in the Coagadex pack) and

draw air into the syringe by pulling the plunger to the volume of water added in step 4.

  • • Attach the syringe to the transparent part of the transfer device and

push the air contained in the syringe into the vial.

Pre-filled syringe with transparent liquid and protective needle cap in an open transparent blister pack

Step 6

  • Immediately turn the solution vial upside down, which will be drawn into the syringe.
  • Detach the filled syringe from the device.
  • • The product is now ready for use. For administration, follow normal safety procedures. Ensure the product is used within one hour of constitution.

Do not use this medicine:

  • if the solvent does not pass into the vial (this indicates loss of vacuum in the vial, in which case the powder should not be used).
  • if the dissolved powder and solvent form a gel or clot (if this happens, inform your healthcare provider, reporting the batch number printed on the vial).

If you use more Coagadex than you should

If you administer more of this medicine than prescribed by your doctor, you may develop a blood clot. If you think you are using too much product, stop the injections and consult your doctor, pharmacist, or nurse. If you know you have used too much, inform your doctor, pharmacist, or nurse as soon as possible.

If you forget to use Coagadex

Do not use a double dose to make up for forgotten doses. Inject your normal dose when you remember and continue the administration as indicated by your doctor.

If you stop treatment with Coagadex

Always consult your doctor before deciding to stop your treatment.

If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Allergic reactions (hypersensitivity reactions) have occurred rarely (may affect up to 1 in 1,000 people) in the treatment of coagulation disorders with similar medicines, and have sometimes progressed to shock. These can be signs of hives, tingling, flushing, nausea, vomiting, headache, wheezing, chest tightness, chills, rapid heart rate, dizziness, lethargy, restlessness, facial swelling, throat tightness, and discomfort at the infusion site. If you experience any of these side effects, contact your doctor.

The following side effects have been reported with Coagadex.

Common (may affect up to 1 in 10 people):

  • pain or redness at the infusion site
  • fatigue
  • back pain

Side effects in children and adolescents

It is expected that the side effects in children will be the same as in adults.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible that the side effects are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Coagadex

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the cartons after “EXP”. The expiry date refers to the last day of the month shown.

Do not store above 30°C. Do not freeze.

Store the pack in the outer carton to protect from light.

Do not use this medicine if you notice small particles in the dissolved product. Once constituted, Coagadex must be used within one hour.

Medicines should not be disposed of via wastewater or household waste. Your treatment center will provide a special container for disposing of any remaining solution, used syringes, needles, and empty vials. This will help protect the environment.

6. Container contents and additional information

Coagadex composition

  • The active ingredient is human coagulation factor X. One vial contains 250 IU or 500 IU of nominal human coagulation factor X.
  • The other components are: citric acid, disodium phosphate dihydrate, sodium chloride,
  • sodium hydroxide, and sucrose (see section 2 for more information on the components).

Solvent: water for injectable preparations.

Appearance of Coagadex and container contents

Coagadex is a white or off-white powder, packaged in quantities of 250 IU and 500 IU. Once constituted, the solution is colorless, transparent, or pearlescent (opalescent). Before injection, examine the solution. If it is turbid or contains particles, do not use it.

A Mix2Vial transfer device is also provided.

Contents of the 250 IU container

1 vial with 250 IU of powder

1 vial with 2.5 ml of water for injectable preparations

1 transfer device (Mix2Vial)

Contents of the 500 IU container

1 vial with 500 IU of powder

1 vial with 5 ml of water for injectable preparations

1 transfer device (Mix2Vial)

Only certain container sizes may be marketed.

Marketing authorization holder

BPL Bioproducts Laboratory GmbH

Dornhofstraße 34, 63263 Neu-Isenburg

Germany

Manufacturer

PharmaKorell GmbH, Georges-Köhler-Str. 2, 79539 Lörrach, Germany

You can request more information about this medication by contacting the local representative of the marketing authorization holder:

Belgium

Bio Products Laboratory Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Lithuania

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Text with contact information of BPL Bioproducts Laboratory GmbH including phone, email, and country of origin

Luxembourg

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Czech Republic

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Hungary

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Denmark

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Malta

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Germany

BPL BioProducts Laboratory GmbH

Tel: +49 (0) 2408 146 0245

e-mail: [email protected]

Germany

Netherlands

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Estonia

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Norway

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Greece

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Austria

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Spain

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Poland

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

France

Laboratoire Cevidra

Tel: +33 493705831

e-mail: [email protected]

France

Portugal

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Croatia

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Romania

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Ireland

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Slovenia

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Iceland

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Slovak Republic

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Italy

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Finland

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Cyprus

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Sweden

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Latvia

BPL BioProducts Laboratory GmbH

Tel: +44 (0) 20 8957 2255

e-mail: [email protected]

(United Kingdom)

Date of last revision of this leaflet:

Detailed information on this medication is available on the European Medicines Agency website: http://www.ema.europa.eu.

Online doctors for COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION

Discuss questions about COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
0.0 (0)
Doctor

Hocine Lokchiri

General medicine 21 years exp.

Dr. Hocine Lokchiri is a French consultant with over 20 years of experience in General and Emergency Medicine. He works with adults and children, helping patients with urgent symptoms, infections, sudden health changes and everyday medical concerns that require timely evaluation. His background includes clinical practice in France, Switzerland and the United Arab Emirates, which allows him to navigate different healthcare systems and manage a wide range of conditions with confidence. Patients value his calm, structured approach, clear explanations and evidence-based decision-making.

Online consultations with Dr. Lokchiri are suitable for many situations when someone needs quick medical guidance, reassurance or a clear next step. Common reasons for booking include:

  • fever, chills, fatigue and viral symptoms
  • cough, sore throat, nasal congestion, breathing discomfort
  • bronchitis and mild asthma flare-ups
  • nausea, diarrhoea, abdominal pain, digestive infections
  • rashes, allergic reactions, redness, insect bites
  • muscle or joint pain, mild injuries, sprains
  • headache, dizziness, migraine symptoms
  • stress-related symptoms, sleep disturbances
  • questions about test results and treatment plans
  • management of chronic conditions in stable phases
Many patients reach out when symptoms appear suddenly and cause concern, when a child becomes unwell unexpectedly, when a rash changes or spreads, or when it’s unclear whether an in-person examination is necessary. His emergency medicine background is particularly valuable online, helping patients understand risk levels, identify warning signs and choose safe next steps.

Some situations are not suitable for online care. If a patient has loss of consciousness, severe chest pain, uncontrolled bleeding, seizures, major trauma or symptoms suggesting a stroke or heart attack, he will advise seeking immediate local emergency services. This improves safety and ensures patients receive the right level of care.

Dr. Lokchiri’s professional training includes:

  • Advanced Trauma Life Support (ATLS)
  • Basic and Advanced Cardiac Life Support (BLS/ACLS)
  • Pediatric Advanced Life Support (PALS)
  • Prehospital Trauma Life Support (PHTLS)
  • eFAST and critical care transthoracic echocardiography
  • aviation medicine
He is an active member of several professional organisations, including the French Society of Emergency Medicine (SFMU), the French Association for Emergency Physicians (AMUF) and the Swiss Society of Emergency and Rescue Medicine (SGNOR). In consultations, he works with clarity and precision, helping patients understand their symptoms, possible risks and the safest treatment options.
Camera Book a video appointment
€58
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
The active ingredient in COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION is coagulation factor X. This information helps identify medicines with the same composition but different brand names.
Who manufactures COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION is manufactured by Bpl Bioproducts Laboratory Gmbh. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to COAGADEX 250 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION?
Other medicines with the same active substance (coagulation factor X) include COAGADEX 500 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION, ADVATE 1,000 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION, ADVATE 1500 IU POWDER AND SOLVENT FOR INJECTABLE SOLUTION. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media